rna-epigenetics
(3)
Jerry McMahon
Dr. Jerry McMahon is the President and CEO of STORM Therapeutics, a Cambridge, UK biotech pioneering drugs that target RNA modifying enzymes. A biochemist-turned-operator with more than 30 years in oncology drug development, he has led biotechs from bench to IPO, helped bring the cancer drug sunitinib (Sutent) to patients, and now steers STORM's first-in-class METTL3 inhibitor STC-15 through the clinic - the first RNA modification enzyme inhibitor ever to enter human trials.
Marguerite Hutchinson
Marguerite Hutchinson, J.D., is the Chief Business Officer of STORM Therapeutics, a Cambridge, UK clinical-stage biotech advancing the first RNA methyltransferase inhibitor into clinical development. A Harvard graduate and lawyer by training, she has spent more than a decade turning early science into deals - building licensing partnerships with Roche, Merck, AstraZeneca, AbbVie and Cancer Research UK, founding and funding a UCSF spin-out, and steering a first-in-class cancer drug through to approval. She was named one of the Top 25 Women Leaders in Biotechnology.
STORM Therapeutics
STORM Therapeutics is a Cambridge, UK biotechnology company pioneering the field of RNA epigenetics. It designs small-molecule inhibitors of RNA-modifying enzymes to treat cancer and other diseases. Its lead drug, STC-15, is the first RNA-modifying enzyme inhibitor to reach human clinical trials, now in a Phase 2 study for sarcoma.